EUVIMEDOpdag EUVIMED
Netzwerk-MetaanalyseÜbersichtsarbeit

Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

Xin-Hui Pan, Bryan Tan iD, Yip Han Chin iD, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh iD, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R Grandhi, Georgios K Dimitriadis iD and 5 more

Obesity · 2024

DOI: 10.1002/oby.24002 ↗

At a glance

Netzwerk-Metaanalyse in Obesity, 2024. Written by Xin-Hui Pan and 16 co-authors. Institution: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Major MEDLINE topics: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight. Cited 73 times so far (Crossref); 100 references. Funded by: MOMMENTUM-CVD centre grant to the National University Heart Centre, National University Health System Seed Fund, National Medical Research Council Clinician-Scientist Award Senior Category.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This network meta‐analysis evaluates the efficacy and safety of tirzepatide compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss drugs in the treatment of overweight and obesity.

Methods

MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP‐1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta‐analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects.

Results

Thirty‐one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight‐related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42–16.34). As compared to placebo, tirzepatide and GLP‐1 RA across all doses had significant increases in gastrointestinal adverse effects.

Conclusions

The superiority of tirzepatide and GLP‐1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityOverweightHumansGlycated HemoglobinRandomized Controlled Trials as TopicTirzepatideTreatment OutcomeTriglyceridesWeight Loss

Substances

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinTirzepatideTriglycerides

Authors and institutions

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Ministry of Health Holdings, Ministry of Health, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
  • Royal College of Surgeons in Ireland & University College Dublin Malaysia Campus, George Town, Malaysia.
  • Department of Endocrinology, National University Hospital, Singapore.
  • VCU Health Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID profiles: Bryan Tan, Yip Han Chin, Martin Kueh, Georgios K Dimitriadis, Nicholas W S Chew, Carel W Le Roux

Funding

  • MOMMENTUM-CVD centre grant to the National University Heart Centre
  • National University Health System Seed Fund
  • National Medical Research Council Clinician-Scientist Award Senior Category
  • National Medical Research Council Research Training Fellowship

Cite

APA

Pan, X. H., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Le Roux, C. W., Mamas, M. A., & Chan, M. Y. (2024). Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. https://doi.org/10.1002/oby.24002

Vancouver

Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, et al. Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. 2024. doi:10.1002/oby.24002

BibTeX
@article{Pan2024,
  author = {Pan, Xin-Hui and Tan, Bryan and Chin, Yip Han and Lee, Ethan Cheng Zhe and Kong, Gwyneth and Chong, Bryan and Kueh, Martin and Khoo, Chin Meng and Mehta, Anurag and Majety, Priyanka and Grandhi, Gowtham R and Dimitriadis, Georgios K and Foo, Roger and Chew, Nicholas W S and Le Roux, Carel W and Mamas, Mamas A and Chan, Mark Y},
  title = {Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24002}
}
Start for free →